Aside from limiting inflammation, the upregulation of HO-1 by canagliflozin attenuates oxidative stress in diabetes leading to increases in nitric oxide bioavailability and improvements in endothelium-dependent vasodilation and hypertension [22,23,24,25]. Here, HMOX1 is linked to diabetes mellitus.